AFT Pharmaceuticals Targets Niche Dermatology Upside With New Rapamycin Port Wine Stain Trial

AFT Pharmaceuticals Ltd. (AU:AFP) announced an update on their ongoing clinical study.

AFT Pharmaceuticals Ltd. (AU:AFP) is launching a Phase II clinical trial titled “Rapamycin Dose-Ranging Efficacy Study: A Phase II, Proof of Concept, Double-blind, Placebo-controlled, Randomized, Parallel-group, Dose-response Comparison of the Effects of Different Strengths of Rapamycin Cream Applied Topically in Subjects Diagnosed With Port Wine Stains.” The study will test if adding a rapamycin cream to standard laser therapy improves the look of port wine stain birthmarks, a visible skin condition with limited treatment options.

The trial evaluates a topical rapamycin cream used with pulsed dyed laser, the current standard device treatment for these birthmarks. Two strengths of rapamycin cream, 0.6% and 1.0%, will be compared with a placebo cream to see which dose gives the best balance of benefit and safety.

This is an interventional, randomized Phase II study that assigns patients by chance to one of three groups. It is double-blind and placebo-controlled, meaning neither patients nor study staff know who gets active cream or placebo, and the main goal is to test if the treatment works better than standard care alone.

The study is listed as “Not yet recruiting,” signaling work is still under way to start enrolling patients. Key dates include initial submission on 22 Feb 2026, with the latest protocol update filed on 26 Feb 2026, which confirms the design and keeps investors informed of near-term development milestones.

For investors, this update marks a new proof-of-concept asset in AFT’s pipeline targeting a niche yet visible dermatology market. If early results show clear cosmetic benefit on top of laser therapy, AFT could gain a differentiated product versus general dermatology players and laser-only approaches, which could lift sentiment and support a valuation re-rating.

The study also positions AFT in a space where large dermatology and aesthetics companies track innovation, potentially improving partnership or licensing options. While the trial is still early stage and carries usual development risk, the clear clinical need and device-plus-drug angle may be seen as a modest positive catalyst as the study progresses.

The rapamycin dose-ranging study in port wine stains is now formally posted and advancing toward recruitment, with ongoing updates and full protocol details available on the ClinicalTrials portal.

To learn more about AU:AFP’s potential, visit the AFT Pharmaceuticals Ltd. drug pipeline page.